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conditioning (13% vs. 9%, P¼1.000). PFS at 1 year was slightly
higher for ATG1 (52.8% vs. 45.5%,P ¼ .955), while OS at 1 year
was not different between the two groups (53.7% vs 55.4%,P
¼ .779).
Conclusion: A small decrease in the prophylactic ATG dose
(1.5mg/kg) had a signiﬁcant clinical impact. An increased
incidence of severe lethal acute GVHD was observed with
4.5mg/kg dosing despite a greater degree of HLA-matching.
The 6.0mg/kg dosing prevented grade IV acute GVHD and
associated mortality. Further research is warranted to ﬁnd
the optimal dosing regimen prior to allogeneic stem cell
transplantation.431
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Background: Previous studies have shown that patients
receiving AHSCT are likely to have sub-optimal Vit D levels.
Vit D has also been shown to have signiﬁcant immuno-
modulatory effects, including polarization of T cell pop-
ulation towards Th2 expression and decreasing allogeneic
T-cell proliferation while increasing T-reg cell function.
Alloreactive T cells upregulate the Vit D receptor and reple-
tion of Vit D in vitro signiﬁcantly reduces this response. Thus
it is hypothesized that patients with VIT D deﬁciency at onset
of AHSCTwould have greater incidence and severity of GVHD
and that early replacement may lessen the risk of GVHD. In
this study we examine this relationship.
Methods: A retrospective evaluation of 290 adult AHSCT at
the University of Michigan between January 2007-December
2010. All patients had Serum 25-hydorxyvitamin D (25OHD)
levels at admission for AHSCT. Deﬁcient levels were deﬁned
to be below 29 ng/ml and normal levels as 30 ng/ml or
higher. The incidence and grade of GVHD were deﬁned as
maximum overall grade and acute GVHD was deﬁned as
starting within the ﬁrst 100 days. The primary standard
GVHD prophylaxis regimens were Tacrolimus/MTX for full
intensity and Tacrolimus /MMF for reduced intensity
transplants.
Results: Of all AHSCT 77% had Vit D deﬁciency at onset of
transplant with no difference between related donors (RD)
and unrelated donors (UD). Vit D supplementation was
started within the ﬁrst week of transplant and occurred in
83% who were Vit D deﬁcient at baseline and 36% of those
having normal levels at baseline. In patients with baseline Vit
D deﬁciency there did not appear to be an impact of Vit D
supplementation on the incidence of Grade 2-4 GVHD (44%
vs 46%) or Grade 3-4 GVHD (17% vs 19%). However in patients
who had baseline Vit D levels of 30 ng/ml or above there was
a signiﬁcant decrease in the incidence of Grade 3-4 GVHD in
the group who received Vit D supplementation versus those
who did not (9% vs 27%, X2¼2.99,P ¼ .042) and a trend
towards a decrease in Grade 2-4 GVHD (35% vs 54%,
X2¼2.11,P ¼ .073). This is despite having more Unrelated
Donor transplants in the Vit D supplemented group (65% vs
46%).Conclusion: AHSCT patients have high rates of Vit D deﬁ-
ciency. Ironically this study suggests that Vit D supplemen-
tation starting during transplant may signiﬁcantly decrease
the incidence of Grade 3-4 GVHD in patients who have
baseline levels >30 ng/ml but not those severely deﬁcient at
baseline. This could imply that higher amounts of Vit D
supplementation may be required to adequately effect T cell
response. Future trials should evaluate the role of increasing
Vit D supplementation and determine if an optimal Vit D
level is required to decrease the incidence and severity of
acute GVHD.432
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Chronic graft-versus-host disease (cGVHD) remains a major
cause of late phase mortality and morbidity after allogeneic
hematopoietic stem cell transplantation.We investigated the
roles of the PD-1 pathway in cGVHD using a well-deﬁned
mouse model (B10.D2 into BALB/c). First, we conﬁrmed that
CD4 and CD8 cells from the spleen and peripheral lymph
nodes (PLN) of allogeneic recipients expressed signiﬁcantly
more PD-1 compared to those of syngeneic recipients on
days 14, 21, 28, and 56 after transplantation (p < 0.05). Upon
transferring PD-1 KO donor T cells of the B10.D2 background
into allogeneic bone marrow transplantation (BMT) models,
there was severe weight loss and 100% of the recipients died
by day 23. To avoid early death and to examine the roles of
the PD-1 pathway in cGVHD, we next administered six
antibody doses to recipients of wild-type (WT) donors from
day 14 of BMT, just prior to the development of cGVHD. Mice
treated with anti-PD-1 showed 70% mortality by day 35 in
contrast to only 10% mortality in those administered anti-
B7H1 Ab or anti-B7DC Ab. All groups treated with anti-PD-1
Ab, anti-B7H1 Ab, or anti-B7DC Ab had signiﬁcantly higher
cGVHD scores than controls (anti-PD-1 Ab: 2.510.31, anti-
B7H1 Ab: 2.310.15, anti-B7DC Ab: 2.010.42, vs. control:
1.180.27, P < .05). To further examine the roles of the PD-1
pathway in cGVHD, we next used B7H1 KO mice as recipi-
ents. Allogeneic B7H1 KO BMT recipients showed signiﬁ-
cantly more severe skin cGVHD than WT controls (p < 0.05).
Histopathological examination of the skin showed signiﬁ-
cantly increased cGVHD damage in recipients of B7H1 KO
donors (5.86  0.85 vs. 8.38  0.38, P < 0.05). Since B7H1
expression of hematopoietic cells is critical for donor Treg
cell expansion, we then harvested cells from PLNs 14 and 28
days after BMT and analyzed cytokine expression levels.
Recipients of B7H1 KO showed fewer Foxp3+ regulatory T
cells in the early phase (day 14), whereas there was no
difference in the frequency of Foxp3+ regulatory T cells in the
late phase (day 28). We previously reported that Th1 and
Th17 cells contribute to the pathogenesis of cGVHD using this
mouse model. On day 28, IL-17+ IFNg+ T cells were detected
signiﬁcantly more frequently in recipients of B7H1 KO
donors than those of WT recipients (p < 0.05). These results
suggested that B7H1 expression in the recipient regulates
the frequency of IL-17+ IFNg+ T cells and Foxp3+ regulatory T
cells. Finally, we established chimeras that expressed B7H1
in hematopoietic cells, but not in parenchymal tissue by
transferring WT BM cells into B7H1KO recipients. Chimeric
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mice (WT BM cells intoWT recipients), suggesting the role of
host parenchymal tissue cell expression of B7H1 in cGVHD.
Taken together, the PD-1 axis, especially B7H1 expression on
recipients, regulates the frequency of IL-17+ IFNg+ T cells and
contributes to the pathogenesis of cGVHD.433
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Between September 2010 and June 2012, 15 patients with
SAA underwent HLA identical sibling donor SCT using Flu-
darabine 180 mg/m2 IV over 6 days and Cyclophosphamide
100 mg/kg IV over 2 days. Five patients had in addition
a single fraction of Total Body irradiation (TBI) 200 cGy.
Cyclophosphamide 50 mg/kg/day IV on day +3 and +4 was
the sole GVHD prophylaxis. G-CSF mobilized peripheral
blood stem cells (PBSC) was the graft source. Tenmales and 5
females with a median age of 25 years (range: 8 e 42) had
SCT. Median PBSC cell dose infused was 9.5 x 106 CD34/Kg
(range: 5.4 e 17.2). Thirteen engrafted (86.6%) with median
neutrophil and platelet engraftment of 15.4 days (range: 15-
17) and 16.6 days (range: 12-32) respectively. Grade IIeIV
GVHD seen in 3 patients (23%) at 42, 49 and 68 days post SCT.
Two responded to combination of cyclosporine and pred-
nisolone while one patient with grade IV GVHD expired 64
days post SCT. Of 11 evaluable patients, 4 (36.3%) developed
chronic GVHDwhich was limited in all. Two patients with de
novo chronic GVHD were managed with prednisolone alone.
Overall 7 patients (46.6%) have not required any immuno-
suppression after SCT while 3 have required immunosup-
pressive therapy for 114, 127 and 225 days respectively At
a median follow up of 11 months (range: 1 e 22), 11 (73.3%)
are alive and well including 7 patients who did not require
any immunosuppressive therapy following SCT. The use of
post transplant cyclophosphamide as GVHD prophylaxis
following sibling donor transplant for SAA is associated with
low rates of GVHD. A large number (46%) did not require any
immunosuppression post SCT. Larger studies are required to
understand the utility of this prophylaxis in sibling donor
transplants for aplastic anemia.434
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blative HCT in pediatric hematologic malignancies is related
to a high risk of relapse. We initiated a prospective study of
FWI and DLI in patients with MC at 30 days post-transplant.
We are reporting preliminary results on 43 enrolled patients
with a mean age of 106.5(SD) years. Fifty-eight percent of
patients had myeloid malignancies, 40% lymphoid malig-
nancies and 2% had biphenotypic leukemia. Based on day +30
bone marrow and peripheral blood chimerism results, 26/43
(60%) patients were found to have MC, and were assigned to
the intervention arm of the study consisting of FWI and DLI;
12 patients (28%) had full donor chimerism (FDC) or early
graft-versus host disease (GVHD) and were assigned to
observation arm, and 5 (12%) could not be assigned to either
arm due to early death or relapse. FWI started at a median of
day +50 (range 40-85), and ended at a median of day +75.5
(range 49-113). Following FWI, 9 patients (35%) converted to
FDC. Of 17 patients who remained MC following FWI, 15
proceeded to DLI, 1 did not receive further intervention due
to GVHD and one relapsed prior to DLI. Acute GVHD devel-
oped in 3/26 (12%) patients undergoing FWI and in 9/12
(75%) of patients in the observation arm (P < .01). Two
patients undergoing intervention developed grade II aGVHD
which resolved and 1 developed grade IV aGVHD that pro-
gressed to fatal cGVHD of the lungs. In the observation arm, 2
patients developed grade I, 5 developed grade II, 2 developed
grade III, and 1 developed grade IV aGVHD. Chronic GVHD
developed in 6 patients (2 in the intervention and 4 in the
observation arm). One of 6 patients developed de novo
cGVHD, following DLI. The incidence of acute and/or chronic
GVHD was 15% in the intervention arm of the study. Toxic
death rate due to GVHD was 4%. There were 11 events (3
treatment-related deaths and 8 relapses). Mean follow-up of
living patients was 17.610 (SD) months. EFS for the entire
cohort was 717(SD)% and was not signiﬁcantly different
between the observation arm and the intervention arm. Ten
patients (23%) had evidence of disease by ﬂow or cytoge-
netics, at the time of HCT. Based on chimerism results, 4 were
assigned to the intervention arm, 3 to the observation arm,
and 3 could not be assigned to any arm of the study due to
early relapse or death. EFS was signiﬁcantly lower in patients
with positive disease prior to transplant than in those
without evidence of disease (EFS 2715% vs. 867%). Among
26 patients undergoing intervention, relapse was signiﬁ-
cantly more common (P ¼ .014) in patients with positive
disease pre-transplant. Our data indicate that post-trans-
plant immunomodulation is safe and has overall low GVHD
risk (15%). Our schedule of FWI was not adequate to prevent
relapse in patients coming to transplant with persistent
disease. We would recommend an earlier, (day 30) and more
aggressive schedule of immunosuppression withdrawal for
these patients.435
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Background: GVHD is still a major obstacle in allogeneic
transplantation despite the progress of immunosuppressive
drugs and cell therapy such as mesenchymal stem cells.
GVHD is caused by donor lymphocytes, mainly T cells,
